Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis.
Raj Chovatiya, Marjolein de Bruin-Weller, Andrew Alexis et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of phase III trials assessed head, neck, and face (HNF) outcomes with lebrikizumab in adolescents and adults with moderate-to-severe atopic dermatitis. Among patients who responded at week 16 and continued lebrikizumab 250 mg every four weeks, HNF responses were generally maintained through week 152: 94.8% retained HN EASI 75, 82.9% HN EASI 90, and 85.3% HN EASI 100 responses. The analysis also reported facial Investigator’s Global Assessment 0 in patients with skin of color and in those previously exposed to dupilumab.
Key findings
- At week 152, 94.8%, 82.9%, and 85.3% of week 16 responders maintained HN EASI 75, 90, and 100 responses, respectively.
- Stable response through week 152 was observed in 88.8% for HN EASI 75, 80.0% for HN EASI 90, and 74.0% for HN EASI 100.
- At week 152, 93.8% achieved HN EASI ≤1 and 69.2% achieved HN EASI = 0.
- At week 24, F-IGA 0 was achieved by 61% of lebrikizumab-treated patients with skin of color and 55% of those with prior dupilumab exposure.
Why it matters
HNF involvement can substantially affect quality of life, and these findings add long-term data for a clinically important disease area. The reported persistence of response, including in populations with skin of color or prior dupilumab exposure, helps characterize lebrikizumab outcomes across groups represented in the trials.
What to keep in mind
This was a post hoc analysis, and the week 152 durability results were reported among week 16 responders, rather than all treated patients.